[go: up one dir, main page]

MX381947B - Mirna natural para controlar la expresion de gen y uso del mismo. - Google Patents

Mirna natural para controlar la expresion de gen y uso del mismo.

Info

Publication number
MX381947B
MX381947B MX2017008587A MX2017008587A MX381947B MX 381947 B MX381947 B MX 381947B MX 2017008587 A MX2017008587 A MX 2017008587A MX 2017008587 A MX2017008587 A MX 2017008587A MX 381947 B MX381947 B MX 381947B
Authority
MX
Mexico
Prior art keywords
region
strand sequence
mirna
gene expression
control gene
Prior art date
Application number
MX2017008587A
Other languages
English (en)
Other versions
MX2017008587A (es
Inventor
Eriko Aoki
Shiori Kato
Tadaaki Ohgi
Yasuhiko Yoshida
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of MX2017008587A publication Critical patent/MX2017008587A/es
Publication of MX381947B publication Critical patent/MX381947B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un miRNA de tipo natural caracterizado porque:, el miRNA de tipo natural es un ácido nucleico de cadena sencilla que contiene una región X y una región Y; el término 3' de dicha región X y el término 5' de dicha región Y están enlazados a través de una región de enlace de una estructura no nucleótida; la región X comprende (a) una secuencia de cadena guía o (b) una secuencia de cadena pasajera de un miRNA maduro; en caso de (a), la región Y contiene una secuencia de cadena pasajera de este miRNA maduro; mientras que en caso de (b), la región Y contiene una secuencia de cadena guía de este miRNA maduro, y la secuencia de cadena guía y la secuencia de cadena pasajera forman una estructura de cadena doble.
MX2017008587A 2014-12-27 2015-12-25 Mirna natural para controlar la expresion de gen y uso del mismo. MX381947B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014266918 2014-12-27
JP2015130496 2015-06-29
PCT/JP2015/086378 WO2016104775A1 (ja) 2014-12-27 2015-12-25 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途

Publications (2)

Publication Number Publication Date
MX2017008587A MX2017008587A (es) 2017-10-20
MX381947B true MX381947B (es) 2025-03-11

Family

ID=56150787

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008587A MX381947B (es) 2014-12-27 2015-12-25 Mirna natural para controlar la expresion de gen y uso del mismo.

Country Status (14)

Country Link
US (1) US11027023B2 (es)
EP (1) EP3239297B1 (es)
JP (1) JP6471176B2 (es)
KR (1) KR20170098914A (es)
CN (1) CN107109415B (es)
AU (1) AU2015368293B2 (es)
BR (1) BR112017013664A2 (es)
CA (1) CA2971827A1 (es)
ES (1) ES2872527T3 (es)
IL (1) IL252880B (es)
MX (1) MX381947B (es)
RU (1) RU2740032C2 (es)
SG (1) SG11201705223XA (es)
WO (1) WO2016104775A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088524A4 (en) 2013-12-26 2017-08-09 Tokyo Medical University Artificial mimic mirna for controlling gene expression, and use of same
CA2935022A1 (en) 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
EP3276003B1 (en) 2015-03-27 2022-07-20 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
EP3584319A4 (en) 2017-02-06 2021-04-14 Nissan Chemical Corporation SINGLE-STRAND OLIGONUCLEOTIDE
JPWO2018182008A1 (ja) * 2017-03-31 2020-02-06 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
JPWO2019074110A1 (ja) * 2017-10-13 2020-12-24 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
MX2020009765A (es) 2018-03-20 2021-01-08 Tokyo Inst Tech Oligonucleotido antisentido reducido en toxicidad.
CN115490768B (zh) * 2021-06-18 2024-11-15 佛山热休生物技术有限公司 Col1a1的表位肽及所述表位肽与热休克蛋白的复合物

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (de) 1942-10-28 1953-04-16 Basf Ag Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2005019453A2 (en) 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP1748078B1 (en) 2001-03-09 2011-01-19 Boston Probes, Inc. Methods, kits and compositions of combination oligomers
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
ATE348104T1 (de) 2001-10-29 2007-01-15 Univ Mcgill Azyklische linker enthaltende oligonukleotide und deren verwendungen
AU2003219900A1 (en) 2002-02-22 2003-09-09 James R. Eshleman Antigene locks and therapeutic uses thereof
EP1495141A4 (en) 2002-03-20 2006-03-22 Massachusetts Inst Technology THERAPY OF HIV
DK1527176T4 (en) 2002-08-05 2017-07-03 Silence Therapeutics Gmbh ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
US20040058886A1 (en) 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
CA2488224A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
AU2004247729A1 (en) 2003-06-12 2004-12-23 Applera Corporation Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
ATE532865T1 (de) 2003-09-30 2011-11-15 Anges Mg Inc Klammerartiges oligonukleotid und dieses enthaltender arzneistoff
JP2007508030A (ja) 2003-10-14 2007-04-05 カーネル・バイオファーマ・インコーポレイテッド 血液脳関門を介してｐｎａを送達するための２相ｐｎａ結合体
WO2005037317A2 (en) 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
EP1789553B1 (en) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a non-phosphate backbone linkage
EP2292757A3 (en) 2004-08-23 2011-11-16 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
WO2006022325A1 (ja) 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. ガラクトース誘導体、薬物担体及び医薬組成物
WO2006024880A2 (en) 2004-08-31 2006-03-09 Sylentis S.A.U. Methods and compositions to inhibit p2x7 receptor expression
AU2005295948A1 (en) 2004-10-12 2006-04-27 The Rockefeller University MicroRNAs
ES2534302T3 (es) * 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
BRPI0519690A2 (pt) 2004-12-30 2009-03-03 Todd M Hauser composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos
US7820629B2 (en) 2006-03-01 2010-10-26 Nippon Shinyaku Co., Ltd. Galactose derivative, drug carrier and medicinal composition
EP2505646A1 (en) 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of CRP
AU2007257423B8 (en) 2006-05-31 2012-02-16 The Regents Of The University Of California Purine analogs
EP1890152A1 (en) 2006-08-14 2008-02-20 Charite Universitätsmedizin-Berlin Determination of renin/prorenin receptor activity
JP2008220366A (ja) 2007-02-16 2008-09-25 National Institute Of Advanced Industrial & Technology 修飾型ｐｎａ／ｒｎａ複合体
JP5145557B2 (ja) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
JP5759673B2 (ja) 2007-03-21 2015-08-05 ブルックヘブン サイエンス アソシエイツ，エルエルシー 組み合わされたヘアピン−アンチセンス組成物および発現を調節するための方法
CN101121934B (zh) 2007-04-11 2011-12-07 哈尔滨医科大学 多靶点miRNA反义核苷酸的制备方法
WO2008137867A2 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising mir34 therapeutic agents for treating cancer
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US20090123501A1 (en) 2007-05-17 2009-05-14 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
CA2691617C (en) 2007-05-31 2020-07-21 University Of Iowa Research Foundation Reduction of off-target rna interference toxicity
US20110212075A1 (en) 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
ES2617877T3 (es) 2007-08-27 2017-06-20 1Globe Health Institute Llc Composiciones de ARN interferente asimétrico y uso de las mismas
US8283331B2 (en) * 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
CA2702180A1 (en) 2007-10-12 2009-04-16 Peter Humphries Method for opening tight junctions
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
US20090131358A1 (en) 2007-11-15 2009-05-21 Alcon Research, Ltd. LOW DENSITY LIPOPROTEIN RECEPTOR-MEDIATED siRNA DELIVERY
JP2011504730A (ja) 2007-11-29 2011-02-17 蘇州瑞博生物技術有限公司 標的遺伝子の発現を干渉する複合体分子およびその合成方法
EP4074344A1 (en) 2007-12-04 2022-10-19 Arbutus Biopharma Corporation Targeting lipids
US20110159586A1 (en) 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
EP2256191A4 (en) 2008-02-15 2011-07-06 Riken CYCLIC SINGLE NUCLEIC ACID COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
WO2009123185A1 (ja) 2008-03-31 2009-10-08 独立行政法人産業技術総合研究所 Rna干渉効果が高い2本鎖脂質修飾rna
US20110172295A1 (en) 2008-04-11 2011-07-14 The University Of North Carolina At Chapel Hill METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING
WO2009143619A1 (en) 2008-05-27 2009-12-03 Chum Methods of treating or preventing obesity and obesity-related hypertension
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
WO2010058824A1 (ja) 2008-11-19 2010-05-27 国立大学法人岐阜大学 間葉系細胞の分化を調節するための薬剤及びその利用
EP2411518A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. Rna interference mediated inhibition of the high affinity ige receptor alpha chain (fcerla) gene expression using short interfering nucleic acid (sina)
ES2804764T3 (es) 2009-06-01 2021-02-09 Halo Bio Rnai Therapeutics Inc Polinucleótidos para la interferencia de ARN multivalente, composiciones y métodos de uso de los mismos
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
WO2011028550A1 (en) 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
US8871509B2 (en) 2009-11-06 2014-10-28 Chung-Ang University-Academy Corporation Foundation Nanoparticle-based gene delivery systems
EP3494963A1 (en) 2009-12-18 2019-06-12 The University of British Columbia Methods and compositions for delivery of nucleic acids
AU2010334799A1 (en) 2009-12-23 2012-07-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Influenza targets
SG181904A1 (en) 2009-12-23 2012-07-30 Novartis Ag Lipids, lipid compositions, and methods of using them
AU2011232365A1 (en) 2010-03-24 2012-10-25 Rxi Pharmaceuticals Corporation RNA interference in dermal and fibrotic indications
CN101845071B (zh) 2010-03-25 2012-02-01 北京欧凯纳斯科技有限公司 一种2’或3’偶联氨基酸的核苷衍生物、其制备方法及应用
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
JP5892608B2 (ja) 2010-04-19 2016-03-23 国立研究開発法人理化学研究所 機能性核酸の安定化法
HUE040278T2 (hu) 2010-04-23 2019-02-28 Cold Spring Harbor Laboratory Új szerkezetileg tervezett shRNS-ek
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
SG186899A1 (en) 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
US8618073B2 (en) 2010-07-22 2013-12-31 The University Of North Carolina At Chapel Hill Use of miR-29 for cell protection
ES2443346T3 (es) * 2010-08-03 2014-02-19 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
EP3406730B1 (en) 2010-08-31 2022-02-23 Sirna Therapeutics, Inc. Novel single chemical entities and methods for delivery of oligonucleotides
ES2664992T3 (es) 2010-12-02 2018-04-24 Daiichi Sankyo Company, Limited Polinucleótido monocatenario modificado
CN102559666B (zh) 2010-12-18 2013-12-25 中国科学院上海生命科学研究院 抑制植物病毒的人工miRNA及其构建和用途
EP3178932A1 (en) * 2011-02-03 2017-06-14 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CN102784398B (zh) 2011-05-16 2014-06-18 南京大学 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
WO2012161124A1 (ja) 2011-05-20 2012-11-29 国立大学法人愛媛大学 マイクロｒｎａ又はその発現系を含む組成物
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
JP2013055913A (ja) 2011-09-09 2013-03-28 Bonac Corp 遺伝子発現制御のための一本鎖ｒｎａ分子
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
JP5876890B2 (ja) * 2012-01-07 2016-03-02 株式会社ボナック アミノ酸骨格を有する一本鎖核酸分子
JP2013153736A (ja) * 2012-01-07 2013-08-15 Bonac Corp ペプチド骨格を有する一本鎖核酸分子
ES2765819T3 (es) * 2012-03-04 2020-06-11 Bonac Corp Inhibidor de micro-ARN
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
CN109810977A (zh) 2012-05-26 2019-05-28 株式会社博纳克 具有递送功能的基因表达调控用单链核酸分子
US9856218B2 (en) * 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
BR112015029276B1 (pt) 2013-05-22 2022-07-12 Alnylam Pharmaceuticals, Inc Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
EP3088524A4 (en) 2013-12-26 2017-08-09 Tokyo Medical University Artificial mimic mirna for controlling gene expression, and use of same
CA2935022A1 (en) 2013-12-27 2015-07-02 Bonac Corporation Artificial match-type mirna for controlling gene expression and use therefor
JP6492014B2 (ja) 2013-12-27 2019-03-27 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
US10119140B2 (en) * 2014-04-18 2018-11-06 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of MIR124 and MIR29 in subjects with muscular dystrophy
EP3276003B1 (en) 2015-03-27 2022-07-20 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
HK1259060A1 (en) 2015-12-29 2019-11-22 国立大学法人北海道大学 Single-stranded nucleic acid molecule inhibiting expression of prorenin gene or prorenin receptor gene, and use thereof

Also Published As

Publication number Publication date
AU2015368293A1 (en) 2017-07-13
KR20170098914A (ko) 2017-08-30
MX2017008587A (es) 2017-10-20
BR112017013664A2 (pt) 2018-03-13
IL252880A0 (en) 2017-08-31
ES2872527T3 (es) 2021-11-02
AU2015368293B2 (en) 2021-07-22
CA2971827A1 (en) 2016-06-30
JPWO2016104775A1 (ja) 2017-08-24
EP3239297A1 (en) 2017-11-01
US20180326091A1 (en) 2018-11-15
EP3239297A4 (en) 2018-07-25
WO2016104775A1 (ja) 2016-06-30
CN107109415A (zh) 2017-08-29
CN107109415B (zh) 2021-07-09
EP3239297B1 (en) 2021-03-10
US11027023B2 (en) 2021-06-08
RU2740032C2 (ru) 2020-12-30
IL252880B (en) 2020-10-29
RU2017126566A3 (es) 2019-06-06
JP6471176B2 (ja) 2019-02-13
HK1244032A1 (en) 2018-07-27
SG11201705223XA (en) 2017-07-28
RU2017126566A (ru) 2019-01-28

Similar Documents

Publication Publication Date Title
MX381947B (es) Mirna natural para controlar la expresion de gen y uso del mismo.
DOP2022000085A (es) Composiciones y métodos para inhibir la expresión del gen alas1
EA201991369A1 (ru) Модифицированные направляющие рнк
ZA202002019B (en) Serpinc1 irna compositions and methods of use thereof
BR112016029178A2 (pt) composições e métodos para a expressão de rnas guia de crispr usando o promotor h1
MX385048B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
WO2015188197A3 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
MX382225B (es) Composiciones y metodos para inhibir la expresion del gen de hidroxiacido-oxidasa 1 (glicolato-oxidasa) (hao1).
HK1244843A1 (zh) 载脂蛋白c3(apoc3)irna组合物及其使用方法
MY201504A (en) Complement component c5 irna compositions and methods of use thereof
PH12017500424A1 (en) Mir-29 mimics and uses thereof
MX387332B (es) Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.
MX2016017382A (es) Metodos para preparar analogos de nucleotido sustituidos.
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
AR102777A1 (es) COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO
AR100946A1 (es) Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn
EP4335502A3 (en) Modified u6 promoter system for tissue specific expression
EA201691754A1 (ru) Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение
IN2015DN02699A (es)
MX2017004686A (es) Promotor recombinante con aumento de la expresion especifica de fibra.
MX373848B (es) Composiciones promotoras.
MY185464A (en) Complement component c5 irna compositions and methods of use thereof